lory saveria croce'

Prof. lory saveria croce'

Università degli Studi di Trieste
orcid

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 January 2000 in Annals of Internal Medicine
Verified
Journal Article
Closed access
PDF file
SBSTEFANO Bellentani
STEFANO Bellentani
GSGioconda Saccoccio
Gioconda Saccoccio
FMFlora Masutti
Flora Masutti
LClory saveria croce'
lory saveria croce'
GBGiovanni Brandi
Giovanni Brandi
CTClaudio Tiribelli
Claudio Tiribelli
Although hepatic steatosis is seen with increasing frequency in clinical practice, its prevalence and risk factors are unknown. To investigate the prevalence of and risk factors for hepatic steatosis, such as alcohol consumption and obesity. Cross-sectional, observational study. Participants in the Dionysos Study. 257 participants assigned to one of four categories (67 controls, 66 obese persons, 69 heavy drinkers, and 55 obese heavy drinkers). Ethanol intake, assessed by a validated questionnaire and expressed as daily (g/d) and lifetime (kg) consumption, and body mass, expressed as body mass index. Biochemical tests of liver and metabolic function and hepatic ultrasonography were done. The prevalence of steatosis was increased in heavy drinkers (46.4% [95% CI, 34% to 59%]) and obese persons (75.8% [CI, 63% to 85%]) compared with controls (16.4% [CI, 8% to 25%]). Steatosis was found in 94.5% (CI, 85% to 99%) of obese heavy drinkers. Compared with controls, the risk for steatosis was higher by 2.8-fold (CI, 1.4-fold to 7.1-fold) in heavy drinkers, 4.6-fold (CI, 2.5-fold to 11.0-fold) in obese persons, and 5.8-fold (CI, 3.2-fold to 12.3-fold) in persons who were obese and drank heavily. In heavy drinkers, obesity increased the risk for steatosis by twofold (CI, 1.5-fold to 3.0-fold) (P < 0.001), but heavy drinking was associated with only a 1.3-fold (CI, 1.02-fold to 1.6-fold) increase in risk in obese persons (P = 0.0053). Elevated alanine aminotransferase and triglyceride levels are the most reliable markers of steatosis. Steatosis is frequently encountered in healthy persons and is almost always present in obese persons who drink more than 60 g of alcohol per day. Steatosis is more strongly associated with obesity than with heavy drinking, suggesting a greater role of overweight than alcohol consumption in accumulation of fat in the liver.

1 May 1995 in Journal of Magnetic Resonance Imaging
Verified
Journal Article
Closed access
PDF file
RLRenata Longo
Renata Longo
PPPiero Pollesello
Piero Pollesello
CRClaudio Ricci
Claudio Ricci
FMFlora Masutti
Flora Masutti
BKBjarne J. Kvam
Bjarne J. Kvam
LPLudovico Dalla Palma
Ludovico Dalla Palma

1 July 1997 in Journal of Hepatology
Verified
Journal Article
Closed access
CRClaudio Ricci
Claudio Ricci
RLRenata Longo
Renata Longo
EGEugenio Gioulis
Eugenio Gioulis
MBMarco Bosco
Marco Bosco
PPPiero Pollesello
Piero Pollesello
LPLudovico Dalla Palma
Ludovico Dalla Palma

29 October 2007 in Hepatology
Verified
Journal Article
Open access
PDF file
GBGiorgio Bedogni
Giorgio Bedogni
LMLucia Miglioli
Lucia Miglioli
FMFlora Masutti
Flora Masutti
ACAnna Castiglione
Anna Castiglione
LClory saveria croce'
lory saveria croce'
SBSTEFANO Bellentani
STEFANO Bellentani
Using the general population of the Dionysos Study, we followed up 144 subjects without fatty liver (FL−) and 336 with fatty liver (FL+) for a median time of 8.5 years. All subjects had suspected liver disease (SLD) defined as altered liver enzymes, high mean corpuscular volume, or low platelet count in the absence of HBV and HCV infection. Ethanol intake was assessed using a food frequency questionnaire, and FL was diagnosed using ultrasonography. The incidence and remission rates of FL were 18.5 and 55.0 per 1,000 person-years. Progression to cirrhosis or HCC was rare in both cohorts (incidence rate: 1.7 versus 1.1 and 0.8 versus 0.4 per 1,000 person-years for FL− versus FL+). Multivariable Poisson regression was performed to identify predictors of FL incidence and remission among sex, age, body mass index, ethanol, and liver enzymes. Every increase of 20 g/day of ethanol intake at baseline was associated with a 17% increase in the rate of incident FL ( P = 0.019), a 10% decrease in the rate of remitting FL and SLD ( P = 0.043), a 19% decrease in the rate of remitting FL with persistent SLD ( P = 0.002), and a 10% increase in mortality rate ( P = 0.005) in the FL+ cohort. Conclusion: In the general population of the Dionysos Study, FL regressed in nearly 1 of every 2 cases and had a substantially benign course. Ethanol intake was the most important risk factor for FL remission and incidence and a predictor of mortality in subjects with FL.

1 June 1999 in Gut
Verified
Journal Article
Open access
PDF file
SBSTEFANO Bellentani
STEFANO Bellentani
GPG Pozzato
G Pozzato
GSG Saccoccio
G Saccoccio
MCM Crovatto
M Crovatto
LClory saveria croce'
lory saveria croce'
CTClaudio Tiribelli
Claudio Tiribelli
BACKGROUND The severity, clinical course, and risk of hepatitis C virus (HCV) related chronic liver disease are still rather poorly defined. AIMS To investigate the prevalence, risk factors, and severity of HCV related liver disease in the general population, and investigate whether infection with a specific genotype is associated with an increased risk of cirrhosis or hepatocellular carcinoma. METHODS HCV RNA determination by polymerase chain reaction (PCR) and HCV genotyping were performed in all anti-HCV positive subjects belonging to the Dionysos study (6917 subjects). Diagnosis of cirrhosis and hepatocellular carcinoma was established by liver biopsy in all cases. All the data were analysed by univariate and multivariate statistics in all the cohort. To investigate the natural history of HCV infection, anti-HCV positive subjects were followed up every six months for three years with liver function tests and ultrasonograms. RESULTS The overall prevalence of HCV RNA positivity was 2.3%. Positivity increased progressively with age, and was higher in women (ratio of men to women = 0.7). Genotypes 1b and 2a were the most frequent (42 and 24% of HCV RNA positive patients), with a prevalence of 1 and 0.6% respectively. Intravenous drug use, blood transfusions received before 1990, history of previous hepatitis among the cohabiting, and history of animal (mainly dogs) bites were significantly (p<0.05) associated with HCV infection, independently of age and sex. Multivariate analysis showed that, independently of age, sex, and alcohol intake, genotype 1b infection, with or without coinfection with other genotypes, is the major risk factor associated with the presence of cirrhosis and/or hepatocellular carcinoma. During the three years of follow up, 57 (35%) of the HCV RNA positive subjects had consistently normal alanine aminotransferase and γ-glutamyltransferase values. Two of the 22 HCV RNA positive cirrhotic patients, all drinking more than 90 g of alcohol a day, developed hepatocellular carcinoma (incidence rate = 3.0% per year). CONCLUSIONS In the general population of Northern Italy, HCV infection is widespread, but only less than 50% of the anti-HCV positive subjects, particularly those infected with genotype 1b, are associated with a more severe liver disease. Alcohol consumption greater that 30 g a day significantly aggravates the natural course of the disease.

1 August 2007 in Hepatology
Verified
Journal Article
Open access
PDF file
Marcello PersicoMarcello Persico
Marcello Persico
Mario CapassoMario Capasso
Mario Capasso
EPEliana Persico
Eliana Persico
MSMonica Svelto
Monica Svelto
Roberta RussoRoberta Russo
Roberta Russo
AIAchille Iolascon
Achille Iolascon
The response to antiviral therapy is lower in hepatitis C virus (HCV) patients with genotype 1 than in those with genotype 2. Overexpression of the suppressor of cytokine signaling 3 (SOCS3) gene in liver tissue is associated with a poorer treatment outcome in patients with chronic hepatitis C viral genotype 1. Also, insulin resistance has been implicated in nonresponse to an anti-HCV treatment. To understand why HCV genotype 1 patients respond differently, we investigated SOCS3 gene expression, metabolic syndrome (MS), and the response to therapy in a cohort of patients with HCV-related hepatitis. A total of 198 patients (108 with genotype 1 and 90 with genotype 2) treated with pegylated interferon plus ribavirin were consecutively enrolled in the study. We measured SOCS3 expression in Epstein-Barr virus–transformed lymphoblastoid cell lines derived from peripheral lymphocytes of a subset of 130 patients. MS was more frequent in genotype 1 patients than in genotype 2 patients ( P < 0.01). Nonresponders ( P < 0.01), MS ( P < 0.001), and genotype 1 ( P < 0.001) were significantly related to SOCS3 overexpression. However, SOCS3 levels were higher in nonresponders also, regardless of the genotype ( P < 0.01). In a univariate analysis, the genotype ( P < 0.001), age ( P < 0.001), SOCS3 ( P < 0.001), and MS ( P < 0.001) were significantly related to the response to therapy. However, in a multivariate analysis, SOCS3 was the only independent predictor of the response (odds ratio = 6.7; P < 0.005). Conclusion: We speculate that SOCS3 expression per se may influence the response to antiviral therapy and that the genotype 1b virus might induce its up-regulation. This may account for the different responses to therapy between genotype 1–infected and genotype 2–infected patients. (HEPATOLOGY 2007.)